Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is dedicated to delivering high-quality KLK2 CAR-T products, such as CAR vectors, CAR mRNA, and CAR cells. In addition to our diverse KLK2 CAR-T products, we also provide comprehensive services to assist with the development and optimization of CAR-T therapies. Our comprehensive product portfolio and expert services are designed to facilitate cutting-edge research in the field of CAR-T therapy.
The kallikrein-related peptidase 2 (KLK2) is a member of the kallikrein family of serine proteases. It is primarily expressed in the prostate gland and is associated with the production of semen. KLK2 can cleave the precursor form of prostate-specific antigen (PSA) to generate active PSA. Several studies have shown that altered expression of the KLK2 is associated with various types of cancer, including breast, lung, ovarian, colorectal, and pancreatic cancers. In breast cancer, for example, overexpression of KLK2 has been linked to a more aggressive and metastatic form of the disease.
Fig.1 Schematic of KLK2.1
Associated Disease
Creative Biolabs offers comprehensive in vitro assays to assess the efficacy and safety of anti-KLK2 CAR-T cell therapy, including:
Successful expression of CAR constructs is crucial for their therapeutic application in CAR T-cell therapy. We provide several methods to evaluate anti-KLK2 CAR expression such as flow cytometry, western blotting, and qPCR. These tests can determine if further optimization or modifications are needed to enhance CAR-mediated immune responses.
Creative Biolabs has rich experience in CAR-T cell proliferation tests. To assess anti-KLK2 CAR-T cell proliferation in vitro, cells are cultured in a controlled environment with specific growth factors and nutrients. The cells are stimulated with specific antigens or antigens expressed by cancer cells to trigger their proliferation. The proliferation of CAR-T cells is then evaluated by cell viability test, cell number counting, or by using various techniques such as flow cytometry to track cell division and expansion.
Creative Biolabs performs cytokine release tests to evaluate the functional activity of CAR-T cells. CAR-T cells are incubated with a specific antigen or target cells in a cytokine release test. The concentration of released cytokines in the culture supernatant is then analyzed using various techniques, including ELISA, flow cytometry-based assays, or multiplex cytokine profiling platforms.
CAR-T cytotoxicity tests are essential to assess the effectiveness and safety of CAR-T cell therapy. We provide cytotoxicity tests to help researchers determine the therapeutic potential of CAR-T cells and select the most effective candidates for further development.
Creative Biolabs utilizes various techniques to monitor and assess anti-tumor efficacy in animal models, such as bioluminescence imaging, immunohistochemical analysis of tumor tissue sections, flow cytometry analysis of immune cell populations, and cytokine profiling. This allows us to provide valuable information on the efficacy and safety of CAR-T therapies, helping our clients to make informed decisions about the development of their treatments.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP1797 | Anti-KLK2 (7C8) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | 7C8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1798 | Anti-KLK2 (7C8) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | 7C8 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1799 | Anti-KLK2 (h11B6) h(CD28-CD3ζ) CAR, pCDCAR1 | Humanized | h11B6 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1800 | Anti-KLK2 (h11B6) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Humanized | h11B6 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1801 | Anti-KLK2 (DS1961AB) h(CD28-CD3ζ) CAR, pCDCAR1 | Rabbit | DS1961AB | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1802 | Anti-KLK2 (DS1961AB) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Rabbit | DS1961AB | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1803 | Anti-KLK2 (CBL629) h(CD28-CD3ζ) CAR, pCDCAR1 | Rabbit | CBL629 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1804 | Anti-KLK2 (CBL629) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Rabbit | CBL629 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1805 | Anti-KLK2 (CBLY1-122) h(CD28-CD3ζ) CAR, pCDCAR1 | Rabbit | CBLY1-122 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1806 | Anti-KLK2 (CBLY1-122) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Rabbit | CBLY1-122 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1807 | Anti-KLK2 (5D6) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | 5D6 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1808 | Anti-KLK2 (5D6) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | 5D6 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1809 | Anti-KLK2 (426723) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | 426723 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1810 | Anti-KLK2 (426723) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | 426723 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1811 | Anti-KLK2 (3C5) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | 3C5 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1812 | Anti-KLK2 (3C5) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | 3C5 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1813 | Anti-KLK2 (6B7) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | 6B7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP1814 | Anti-KLK2 (6B7) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | 6B7 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-SB-LX0303 | Anti-KLK2 (7C8) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | 7C8 | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0304 | Anti-KLK2 (20H6) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | 20H6 | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
